Navigation Links
Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C

BARCELONA, Spain--(BUSINESS WIRE)--Apr 14, 2007 - In a late-breaker presentation at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL), researchers today presented data from a planned interim analysis of the PROVE 1 clinical trial, which is the first trial to evaluate short-duration therapy with the investigational hepatitis C protease inhibitor telaprevir (TVR, VX-950) in combination with pegylated interferon (peg-IFN) and ribavirin (RBV) in treatment-naive, genotype 1-infected hepatitis C patients. The data from PROVE 1 demonstrated a high rate of rapid viral response (RVR) in the telaprevir groups and a low rate of on-treatment viral breakthrough, and suggested that 12 weeks of telaprevir-based therapy enabled some patients to clear the virus. Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) is developing telaprevir in collaboration with Tibotec.

"The high rates of RVR observed in the telaprevir groups in PROVE 1, and the fact that some patients have remained persistently viral negative 20 weeks after stopping the 12 weeks of telaprevir-based therapy, suggest that we may be able to shorten the treatment duration in genotype 1 HCV patients," said John McHutchison, M.D., Principal Investigator for the PROVE 1 study and Director of Gastroenterology and Hepatology Research at Duke Clinical Research Institute. "These interim results are encouraging and suggest that high sustained viral response (SVR) rates may be achieved with regimens that are 24 weeks in total duration. We look forward to 24 week follow-up data from the initial group of patients who stopped treatment at 12 weeks, and follow-up data from patients in the study who received 24 weeks of treatment."

PROVE 1 Summary

-- 88% and 79% of patients receiving telaprevir achieved a rapid viral response (RVR) as measured by plasma HCV RNA (less than)30 IU/mL and (less than)10 IU/mL, respectively, at 4 weeks.<
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
(Date:7/14/2014)...  Mylan Inc. (NASDAQ: MYL ) today announced ... Abbott (NYSE: ABT ) whereby ... markets specialty and branded generics business ("the Assets") in an ... receive 105 million shares of the combined company worth approximately ... Friday, July 11, 2014, representing an approximately 21% ownership stake. ...
(Date:7/11/2014)... , July 11, 2014 Patient ... marketing and, consequently, organizations are turning to an ... As part of this evolving approach ... to educate, communicate and engage patients throughout their ... to patient empowerment. By mapping the patient journey ...
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... "Global Hypodermic Needles Market 2014-2018" report to ... A hypodermic needle is a hollow needle ... the body or or to extract fluids from it. ... liquids or to inject substances that cannot be ingested. ...
Breaking Medicine Technology:Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 2Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 3Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 4Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 5Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 6Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 7Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 8Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 9Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 10Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 11New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3
... International Myeloma Workshop held in,Kos, Greece ... with bortezomib, dexamethasone and lenalidomide plus,dexamethasone, ... as a single agent in patients ... 29, 2007 /PRNewswire-FirstCall/ -- Keryx,Biopharmaceuticals, Inc. ...
... 2007--A cervical cancer vaccine has shown 90%,efficacy for prevention ... papillomavirus (HPV) types targeted by,the vaccine, conclude authors of ... of The Lancet., HPV types 16 and 18 account ... there are up to 15,oncogenic HPV types which can ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 2Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 3Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 4Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 5Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 6Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 7Vaccine Can Prevent Cervical Cancer and Precancerous Lesions 2
(Date:7/14/2014)... 14, 2014 According to the Boost Your Bust ... for women who want to learn how to increase the size ... consists of 7 chapters including:, , Chapter 1 ... Chapter 2 – How Natural Breast Enlargement Works , ... Look Bigger , Chapter 4 – The Groundwork , ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 In ... carriers emphasized lower-cost narrow-network products, accountable care organizations ... chose coverage based on price, rather than on ... from seeking care from out-of-network providers. “Using ... Narrow Networks and Exchange Products,” the July ...
(Date:7/14/2014)... EnergyFirst, manufacturer of all-natural ... Permalean for its great products, thriving customer base, ... markets its products as Jim’s Permalean Protein Powders and ... EnergyFirst’s lineup of nutritional products. The Permalean brand ... year. , Founded in 1999, Permalean’s products were designed ...
(Date:7/14/2014)... CA (PRWEB) July 14, 2014 Crystal ... new office in Sacramento. The announcement has been made via ... office. In addition, the announcement has been made in order ... dental services in the Sacramento area. , Crystal Dental offers ... Some of the services offered by Crystal Dental include cosmetic ...
(Date:7/13/2014)... The special two-day sale starts today on the fan-favorite ... code 20SCRUB at the webstore checkout. The sale expires midnight ... Citrus Scrub falls in love with it," says Sublime ... cleanser for face, but can also be used on the ... exfoliate with pleasure, clean pores and wash away dead skin ...
Breaking Medicine News(10 mins):Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 2Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 3Health News:Milliman, FAIR Health Executives to Discuss Data-Based Rate Setting for Out-of-Network Providers in Atlantic Information Services Webinar 2Health News:EnergyFirst Acquires Permalean - Manufacturer of All Natural Protein Bars and Powders 2Health News:EnergyFirst Acquires Permalean - Manufacturer of All Natural Protein Bars and Powders 3Health News:Crystal Dental Announces the Opening of New Office Location in Sacramento 2Health News:Discover the Favorite Sublime Beauty® Citrus Scrub: Special "Two-Day Only" Sale 2
... , ... Physical Examination of Refrigerated Vacuum Pak or Modified Atmosphere Packaged Raw Fish and Fishery ... ship modified atmosphere or vacuum packed, raw seafood into the US. , ... (Vocus) June 7, 2010 -- ...
... The new Acrylic ... clients can purchase this walk in tub for the same cost of a lesser quality fiberglass ... (PRWEB) May 28, ... in tub available. And now clients can purchase this walk in tub for the same cost ...
... skills in the process, experts say , FRIDAY, June 4 ... spent at the beach or lake, afternoon bike rides and ... likely to be lived in the not-so-great indoors, with kids ... , The indoor child phenomenon concerns health experts and environmentalists, ...
... ... advanced site-search and personalization, with easier management tools, obtaining better ROI , ... Rochester, NY and Piscataway NJ ... e-commerce applications and Celebros, a global leader in revenue optimizing solutions for online stores, ...
... Institute (NHLBI) has stopped a clinical trial evaluating a new ... with sickle cell anemia and iron overload because of evidence ... the existing treatment. The 26-site trial, Stroke With ... the ages of 5 and 18 who had already experienced ...
... complications, death in elderly who don,t delay surgery, research ... elderly patients, prompt removal of a suddenly inflamed gallbladder ... shows. , In the study, Dr. Taylor S. Riall, ... Medical Branch in Galveston, and colleagues analyzed data on ...
Cached Medicine News:Health News:FDA Issues Global Raw Packaged Seafood Import Alert: FDAImports.com Reports Numerous International Firms Impacted 2Health News:FDA Issues Global Raw Packaged Seafood Import Alert: FDAImports.com Reports Numerous International Firms Impacted 3Health News:The Walkinbathtub1 Factory After Years in Design Has Released the Most Up to date Acrylic Walk in Tub in the World 2Health News:The Walkinbathtub1 Factory After Years in Design Has Released the Most Up to date Acrylic Walk in Tub in the World 3Health News:Move Childhood Back Outdoors This Summer 2Health News:Move Childhood Back Outdoors This Summer 3Health News:UniteU and Celebros Launch Dynamic Cross-Sell and New Version of Filtered Navigation Search 2Health News:UniteU and Celebros Launch Dynamic Cross-Sell and New Version of Filtered Navigation Search 3Health News:Stroke prevention study in children with sickle cell anemia, iron overload stopped early 2Health News:Stroke prevention study in children with sickle cell anemia, iron overload stopped early 3Health News:Removing Gallbladder Sooner Cuts Costs, Readmissions 2
Our Wrap-Around Back Relief Apron provides front and back protection. It transfer the weight from the shoulder to the waist with the aid of a 6" wide elastic belt. Belts may be ordered in various siz...
A two piece design that provides maximum protection and versatility. Can be ordered with Velcro, buckle, or orthopedic wide belt closures....
The maternity apron is a very critical protection device for the patient and the fetus....
Wolfs unique apron and vest set distributes weight evenly between shoulders and hips. The vest comes with an attached Thyroid collar...
Medicine Products: